Published in JAMA on April 14, 2004
Women's Health Initiative (WHI) | NCT00000611
Prevention of Obesity in Women Via Estradiol Regulation (POWER) | NCT00687739
Hormone Replacement Therapy (HRT) Website Tool | NCT00319072
Perception and Attitude Toward Estrogen Therapy Among Surgically Menopausal Women | NCT00173550
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest (2005) 5.19
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ (2015) 4.29
Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause (2012) 3.32
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med (2010) 2.89
The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health (2013) 2.85
Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. J Womens Health (Larchmt) (2013) 2.81
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int (2008) 2.74
Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids (2007) 2.56
Vascular actions of estrogens: functional implications. Pharmacol Rev (2008) 2.52
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause (2010) 2.50
Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. Neurology (2009) 2.45
Smoking may be considered an established risk factor for sporadic ALS. Neurology (2009) 2.42
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation (2009) 2.41
Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med (2013) 2.38
Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J (2008) 2.36
Beyond frequency: who is most bothered by vasomotor symptoms? Menopause (2008) 2.35
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst (2013) 2.21
Progesterone receptors: form and function in brain. Front Neuroendocrinol (2008) 2.15
Covariate measurement error correction methods in mediation analysis with failure time data. Biometrics (2014) 2.10
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat (2014) 2.10
Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. Arterioscler Thromb Vasc Biol (2008) 2.04
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev (2013) 1.93
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol (2007) 1.88
Perceptions of clinical research participation among African American women. J Womens Health (Larchmt) (2007) 1.86
Attitudes of obstetrician-gynecologists toward the evidence from the Women's Health Initiative hormone therapy trials remain generally skeptical. Menopause (2009) 1.80
Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. Arthritis Rheum (2008) 1.80
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ (2008) 1.78
Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med (2006) 1.76
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Pathways to ischemic neuronal cell death: are sex differences relevant? J Transl Med (2008) 1.71
Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause (2006) 1.71
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
Early menopausal hormone use influences brain regions used for visual working memory. Menopause (2010) 1.67
Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol (2005) 1.65
Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. Menopause (2009) 1.64
The WHI estrogen-alone trial--do things look any better? JAMA (2004) 1.64
Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci U S A (2014) 1.63
Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol (2013) 1.61
Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst (2013) 1.60
The haunting of medical journals: how ghostwriting sold "HRT". PLoS Med (2010) 1.60
Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol (2009) 1.59
Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke (2009) 1.57
Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation. Physiol Genomics (2011) 1.56
Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study. PLoS One (2012) 1.56
Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Menopause (2011) 1.56
Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause (2011) 1.55
Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.55
Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials (2007) 1.54
Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci (2009) 1.54
Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control (2006) 1.54
A lack of ovarian function increases neuroinflammation in aged mice. Endocrinology (2012) 1.53
Surgical menopause and nonvertebral fracture risk among older US women. Menopause (2012) 1.52
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause (2014) 1.50
Short-term (1-2 mo) hormone therapy cessation before mammography. Menopause (2009) 1.50
Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) (2009) 1.49
Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys. Menopause (2013) 1.49
Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res (2010) 1.48
Vasomotor symptoms and coronary artery calcium in postmenopausal women. Menopause (2010) 1.47
Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: The Women's Health Initiative. J Rheumatol (2008) 1.47
Sex differences in caspase activation after stroke. Stroke (2009) 1.47
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study. Menopause (2006) 1.46
Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials. Menopause (2014) 1.46
Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol (2012) 1.46
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials. J Hypertens (2014) 1.45
Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause (2010) 1.45
Efficacy of yoga for vasomotor symptoms: a randomized controlled trial. Menopause (2014) 1.44
The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Res (2013) 1.44
Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst (2015) 1.44
Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment. Menopause (2015) 1.43
Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause (2013) 1.42
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Vitamin D levels and menopause-related symptoms. Menopause (2014) 1.41
Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. Circ Cardiovasc Qual Outcomes (2014) 1.41
Outcomes of deliveries by family physicians or obstetricians: a population-based cohort study using an instrumental variable. CMAJ (2015) 1.40
Further evidence for promoting transdermal estrogens in the management of postmenopausal symptoms. Menopause (2011) 1.40
Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative. J Womens Health (Larchmt) (2010) 1.40
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence. Cancer Epidemiol Biomarkers Prev (2012) 1.39
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation (2006) 11.65
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med (2004) 9.62
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73